CRAIG LOGSDON to Receptor for Advanced Glycation End Products
This is a "connection" page, showing publications CRAIG LOGSDON has written about Receptor for Advanced Glycation End Products.
Connection Strength
1.363
-
RAGE maintains high levels of NF?B and oncogenic Kras activity in pancreatic cancer. Biochem Biophys Res Commun. 2017 11 04; 493(1):592-597.
Score: 0.615
-
A prospective study of soluble receptor for advanced glycation end-products and colorectal cancer risk in postmenopausal women. Cancer Epidemiol. 2016 06; 42:115-23.
Score: 0.140
-
Designing and developing S100P inhibitor 5-methyl cromolyn for pancreatic cancer therapy. Mol Cancer Ther. 2013 May; 12(5):654-62.
Score: 0.111
-
S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clin Cancer Res. 2012 Aug 15; 18(16):4356-64.
Score: 0.107
-
S100P: a novel therapeutic target for cancer. Amino Acids. 2011 Oct; 41(4):893-9.
Score: 0.093
-
RAGE and RAGE ligands in cancer. Curr Mol Med. 2007 Dec; 7(8):777-89.
Score: 0.078
-
Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst. 2006 Dec 20; 98(24):1806-18.
Score: 0.073
-
S100P promotes pancreatic cancer growth, survival, and invasion. Clin Cancer Res. 2005 Aug 01; 11(15):5356-64.
Score: 0.067
-
S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem. 2004 Feb 13; 279(7):5059-65.
Score: 0.059
-
RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis Colon Rectum. 2007 Aug; 50(8):1230-40.
Score: 0.019